Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer

NCT06801236 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

67

Enrollment

INDUSTRY

Sponsor class

Conditions

Prostate Cancer (Adenocarcinoma)
mCRPC (Metastatic Castration-resistant Prostate Cancer)

Interventions

DRUG: ACE-232 tablets

Sponsor

Acerand Therapeutics (Hong Kong) Limited